Cargando…

Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy

Pancreatic neuroendocrine neoplasia constitute an important subentity of the gastroenteropancreatic neuroendocrine neoplasms accounting for up to 15% of all neuroendocrine neoplasm. Prognosis and oncological behavior of pancreatic neuroendocrine tumors (pNETs) is extremely heterogenous and dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Loosen, Sven H., Kostev, Karel, Eschrich, Johannes, Krieg, Sarah, Krieg, Andreas, Luedde, Tom, Jann, Henning, Roderburg, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771158/
https://www.ncbi.nlm.nih.gov/pubmed/36550801
http://dx.doi.org/10.1097/MD.0000000000032044
_version_ 1784854759206813696
author Loosen, Sven H.
Kostev, Karel
Eschrich, Johannes
Krieg, Sarah
Krieg, Andreas
Luedde, Tom
Jann, Henning
Roderburg, Christoph
author_facet Loosen, Sven H.
Kostev, Karel
Eschrich, Johannes
Krieg, Sarah
Krieg, Andreas
Luedde, Tom
Jann, Henning
Roderburg, Christoph
author_sort Loosen, Sven H.
collection PubMed
description Pancreatic neuroendocrine neoplasia constitute an important subentity of the gastroenteropancreatic neuroendocrine neoplasms accounting for up to 15% of all neuroendocrine neoplasm. Prognosis and oncological behavior of pancreatic neuroendocrine tumors (pNETs) is extremely heterogenous and dependent on the specific tumor stage and differentiation. However, systematic data on the specific epidemiology of pNET are scarce. We identified 662 patients with pNET within the Oncology Dynamics database (IQVIA). Patients were derived from 4 European countries (Germany, France, UK, Spain), 3 Asian countries (Japan, China, South Korea) and 2 South American countries (Mexico and Brazil) and with regard to major patient and tumor related characteristics including patients’ age, sex, tumor stage, tumor grading, and differentiation. The mean age of the study cohort was 62 years (SD 12 years) with 53.9.1% of all patients being male. The majority of patients had an Eastern co-operative of Oncology Group 1 performance status (63.3%). The most common Union international contre le cancer tumor stage was stage IV (85%) with liver metastases (89.0%) representing the most common site of extra-pancreatic tumor manifestation. The majority of all patients displayed well or moderate tumor differentiation (9.6% of patients had a Ki-67 expression below 2%. 67.6% of pNET patients had a Ki-67 expression between 2 and 20% and 22.8% of patients showed an expression above 20%). At time point of diagnoses, 93.1% of patients were classified as inoperable. Of note, 93.9 % of patients received systemic anti-tumoral therapy in palliative intention, while treatment was administered in 1.4 % of cases in neoadjuvant and in 4.7% of cases in in an adjuvant setting. Biological therapy was applied to 39.4% of patients, followed by targeted therapies (31.4%) and chemotherapy. Pancreatic neuroendocrine neoplasia are diagnosed in advanced tumor stages, globally. Systemic treatment was the most commonly used treatment modality. Such data may help to better understand the specific epidemiology of pNET worldwide.
format Online
Article
Text
id pubmed-9771158
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97711582022-12-22 Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy Loosen, Sven H. Kostev, Karel Eschrich, Johannes Krieg, Sarah Krieg, Andreas Luedde, Tom Jann, Henning Roderburg, Christoph Medicine (Baltimore) 4500 Pancreatic neuroendocrine neoplasia constitute an important subentity of the gastroenteropancreatic neuroendocrine neoplasms accounting for up to 15% of all neuroendocrine neoplasm. Prognosis and oncological behavior of pancreatic neuroendocrine tumors (pNETs) is extremely heterogenous and dependent on the specific tumor stage and differentiation. However, systematic data on the specific epidemiology of pNET are scarce. We identified 662 patients with pNET within the Oncology Dynamics database (IQVIA). Patients were derived from 4 European countries (Germany, France, UK, Spain), 3 Asian countries (Japan, China, South Korea) and 2 South American countries (Mexico and Brazil) and with regard to major patient and tumor related characteristics including patients’ age, sex, tumor stage, tumor grading, and differentiation. The mean age of the study cohort was 62 years (SD 12 years) with 53.9.1% of all patients being male. The majority of patients had an Eastern co-operative of Oncology Group 1 performance status (63.3%). The most common Union international contre le cancer tumor stage was stage IV (85%) with liver metastases (89.0%) representing the most common site of extra-pancreatic tumor manifestation. The majority of all patients displayed well or moderate tumor differentiation (9.6% of patients had a Ki-67 expression below 2%. 67.6% of pNET patients had a Ki-67 expression between 2 and 20% and 22.8% of patients showed an expression above 20%). At time point of diagnoses, 93.1% of patients were classified as inoperable. Of note, 93.9 % of patients received systemic anti-tumoral therapy in palliative intention, while treatment was administered in 1.4 % of cases in neoadjuvant and in 4.7% of cases in in an adjuvant setting. Biological therapy was applied to 39.4% of patients, followed by targeted therapies (31.4%) and chemotherapy. Pancreatic neuroendocrine neoplasia are diagnosed in advanced tumor stages, globally. Systemic treatment was the most commonly used treatment modality. Such data may help to better understand the specific epidemiology of pNET worldwide. Lippincott Williams & Wilkins 2022-12-16 /pmc/articles/PMC9771158/ /pubmed/36550801 http://dx.doi.org/10.1097/MD.0000000000032044 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4500
Loosen, Sven H.
Kostev, Karel
Eschrich, Johannes
Krieg, Sarah
Krieg, Andreas
Luedde, Tom
Jann, Henning
Roderburg, Christoph
Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
title Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
title_full Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
title_fullStr Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
title_full_unstemmed Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
title_short Clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
title_sort clinical characteristics of 662 patients with pancreatic neuroendocrine tumors receiving antitumoral therapy
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771158/
https://www.ncbi.nlm.nih.gov/pubmed/36550801
http://dx.doi.org/10.1097/MD.0000000000032044
work_keys_str_mv AT loosensvenh clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy
AT kostevkarel clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy
AT eschrichjohannes clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy
AT kriegsarah clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy
AT kriegandreas clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy
AT lueddetom clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy
AT jannhenning clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy
AT roderburgchristoph clinicalcharacteristicsof662patientswithpancreaticneuroendocrinetumorsreceivingantitumoraltherapy